320 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (1940)
- Addiction (18)
- Allergy, Asthma, & Immunology (13)
- All of Us Research Program - NIH (1)
- Autoimmune Disorders (28)
- Blood Disorders (39)
- Bone & Muscle (10)
- Cancer (745)
- Child Development (4)
- COVID-19 (Coronavirus) (36)
- Critical Illness (1)
- Diabetes (21)
- Ear, Nose and Throat (11)
- Endocrine & Metabolic Disease (12)
- Eye (7)
- Gastrointestinal and Digestive Diseases (25)
- Hair and Skin Disorders (3)
- Headaches (5)
- Healthy Volunteers (183)
- Heart Disease (128)
- Infectious Disease (49)
- Insomnia (2)
- Kidney Disease (12)
- Liver Disease (51)
- Lung Disease (31)
- Meniere's Disease (1)
- (-) Neurological Disorders (178)
- Nutrition (7)
- Obesity (9)
- Obstetrics & Gynecology (53)
- Pain Management (1)
- Pediatrics (103)
- (-) Psychiatric Disorders (65)
- Rehabilitation (8)
- Stroke (6)
- Surgery (7)
- Transplant (53)
- Urology (4)
- Vascular Conditions (10)
Displaying 201 - 243 of 243
Condition: Neurological Disorders / Neuropathy
Investigator: Thomas Brannagan, MD
Status: Closed
Peripheral Neuropathy is a result of nerve damage, which may cause weakness, numbness, tingling, and pain in your hands, feet, and other areas of your body. Over 20 million Americans are affected by peripheral neuropathy, most commonly caused by diabetes. In approximately 25-50% of all people with peripheral neuropathy, the cause is unknown. These cases…
Condition: Neurological Disorders
Investigator: Thomas Brannagan, MD
Status: Closed
Patients with Charcot-Marie-Tooth (CMT) disease have a degenerative nerve disease that can cause muscle weakness and decreased muscle size in different muscles in their body. This study drug is designed to evaluate ACE-083 for its ability to increase the size of your muscles, which could improve your muscle strength. The purpose of this research study is…
Condition: Neurological Disorders
Investigator: Cheryl Waters, MD
Status: Closed
This study is for patients with Parkinson's disease. For most patients with Parkinsons disease, doctors use levodopa as a treatment to manage their symptoms. Levodopa pills have been used for many years to treat the symptoms of Parkinsons disease patients. However, with long-term treatment, the effectiveness of levodopa pills often lessens and can lead…
Condition: Neurological Disorders / Brain Tumors
Investigator: Andrew Lassman, MD
Status: Closed
Two different studies have been developed to treat people with anaplastic glioma brain tumors. Onetreatment research study requires a tumor that has the 1p/19q co-deletion tumor marker; the other does not. This treatment research study requires that the subject has a certain kind of tumor, one that is missing part of both chromosomes 1 and 19. These missing…
Condition: Psychiatric Disorders / Anxiety
Investigator: Jonathan Posner, MD
Status: Closed
The goal of this study is to advance our understanding of how the brain processes emotion in adolescents. Adolescents with and without symptoms of anxiety are invited to participate. This study takes place over two days and includes an evaluation and a brain imaging session. Participants will be compensated up to $250. This study does not provide treatment.
Condition: Neurological Disorders / Neuropathy
Investigator: Thomas Brannagan, MD
Status: Closed
The purpose of this study is to see how effective two doses of an investigational new drug called IgPro20 is when given subcutaneously (a shot given into the fat layer between the skin and the muscle) to treat CIDP in patients that still require IVIG and also to look at how safe the IgPro20 is for patients.
Condition: Neurological Disorders / Alzheimer's Disease
Investigator: Davangere Devanand, MD
Status: Closed
The purpose of this study is to evaluate if systematic cognitive training can improve cognitive performance in participants (ages 55-95 years) with memory loss. This study will evaluate the effects of Computerized Cognitive Training (CCT) for improvement in everyday cognitive and function status, in addition to long-term changes in brain networks over an 18…
A study for patients with recurrent glioblastoma or anaplastic astrocytoma using study drug Toca 511
Condition: Neurological Disorders / Brain Tumors
Investigator: Fabio Iwamoto, MD
Status: Closed
This is a research study to test the effectiveness of Toca 511/Toca FC, an experimental drug, for treatment of recurring brain tumors compared to current standard of care. The study will enroll 370 subjects age 18-85 years who choose to undergo removal of the tumor a second time. At the time of surgery patients will be randomly assigned in a 1:1 ratio to…
Condition: Psychiatric Disorders / Obsessive Compulsive Disorder (OCD)
Investigator: Helen Simpson, MD, PhD
Status: Closed
The purpose of this pilot research study is to test whether certain components of the marijuana plant, known as "cannabinoids", may help to reduce symptoms in patients with OCD. Specifically, patients enrolled in the study will smoke marijuana containing different concentrations of 2 different cannabinoids, THC and CBD. Both of these agents act on…
Condition: Neurological Disorders / Alzheimer's Disease
Investigator: Lawrence Honig, MD, PhD
Status: Closed
This study is for patients with Alzheimer's Disease. Alzheimers disease is a disorder characterized by progressive loss of memory, thinking, and behavior. An earlier study in patients having mild to moderate Alzheimers disease has demonstrated more pronounced benefit of treatment with azeliragon among participants with mild disease than among…
Condition: Neurological Disorders / Brain Tumors
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this study is to look at the effects of an investigational anti-cancer drug (BGB-290) in combination with radiation therapy and/or temozolomide in patients with newly diagnosed or recurring glioblastoma. BGB-290 is expected to work by preventing cancer cells from repairing their damaged genes, causing the progression of cancer to slow down.
Condition: Psychiatric Disorders / ADD/ADHD
Investigator: Jonathan Posner, MD
Status: Closed
Children with Attention-Deficit/Hyperactivity Disorder (ADHD) are typically treated with two types of medications: stimulants and non-stimulants. These medications work in different ways to treat ADHD symptoms, but we do not fully understand the brain mechanisms underlying the medications' effects. This study will use MRI scanning to look at changes in…
Condition: Psychiatric Disorders / Anxiety
Investigator: Franklin Schneier, MD
Status: Closed
RESEARCH STUDY:Brief Intervention for Public Speaking Fears (IRB#7293).- Are you between the ages of 18 - 60?- Do you have bothersome fears of public speaking?- Are you interested in trying a novel intervention?This research study tests whether a brief intervention using a medication called propranolol is effective at reducing public speaking fears. This…
Condition: Neurological Disorders / Alzheimer's Disease
Investigator: Yaakov Stern, PhD
Status: Closed
The goal of this study is to investigate whether treatment with the vitamin supplement benfotiamine for one year will slow the memory problems in patients who meet the definition of Alzheimer's disease or amnestic mild cognitive impairment, an early manifestation of Alzheimer's disease.
Condition: Neurological Disorders / Alzheimer's Disease
Investigator: Lawrence Honig, MD, PhD
Status: Closed
The name of this trial is MissionAD. This is a 24-month treatment, multicenter, double-blind, placebo-controlled, parallel group, Phase 3 study in participants with Early Alzheimer's Disease (AD), includingmild cognitive impairment (MCI) due to AD, known as Prodromal AD, and the early stages of mild AD.The study will be conducted to evaluate the…
Condition: Neurological Disorders / Brain Tumors
Investigator: Fabio Iwamoto, MD
Status: Closed
The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of an investigational drug called nivolumab (also known as BMS-936558). Nivolumab is an antibody (a type of human protein) that is being tested to see if it will allow the body's immune system to work against tumor cells.
Condition: Psychiatric Disorders / Obsessive Compulsive Disorder (OCD)
Investigator: Helen Simpson, MD, PhD
Status: Closed
Eligible participants will be asked questions about their symptoms, complete questionnaires, and receive sessions of Cognitive-Behavioral therapy consisting of Exposure and Ritual Prevention (EX/RP) accompanied by the use of a mobile app. The purpose of this study is to assess whether the mobile app may be effective in improving symptoms of OCD.
Condition: Neurological Disorders / Neuromuscular
Investigator: Thomas Brannagan, MD
Status: Closed
This study is designed to test how well an intravenous human immunoglobulin concentrate, IGIV-C (compared with placebo) improves your muscle weakness associated with MG symptoms. A placebo is a medication that looks like the study medication but has no active ingredient. Immunoglobulin is an antibody produced by white blood cells that is used by the immune…
Condition: Neurological Disorders
Investigator: Heakyung Kim, MD
Status: Closed
The purpose of this research study is to check whether an injectable medication called Dysport canrelax the stiffness (spasticity) of the arm muscles and allow your child to improve their ability to use their arm in day to day activities. In addition, this study will check whether treatment with Dysport can lessen the pain caused by spasticity and improve…
Condition: Psychiatric Disorders / Bipolar Disorder
Investigator: Martin Lan, MD
Status: Closed
We are trying to understand what causes bipolar disorder and how medications treat bipolar depression. If you participate, you will have two different brain scans (MRI and PET scan). You will also have antidepressant treatment for free. We will then be able to see whether information on the brain scans connects with how people do on the medications. The…
Condition: Psychiatric Disorders / Bipolar Disorder
Investigator: David Hellerstein, MD
Status: Closed
This study is a double-blind and placebo-controlled study to assess its efficacy of the new drug Lumateperone for patients with Major Depressive Episodes associated with Bipolar I and Bipolar II disorder. Lumateperone is thought to exert its antidepressant effect through interaction with sereotogenic, dopaminergic, and glutamergic neurotransmitter targets.…
Condition: Neurological Disorders / Neuropathy
Investigator: Thomas Brannagan, MD
Status: Closed
The purpose of this study is to collect information about how patients with FAP respond to the study drug ALN-TTR02 over 18 months. This includes studying any potential improvements in FAP and any side effects that participants may have from the study drug. In addition, the study will examine how the body handles (distributes, break down, eliminates) the…
Condition: Neurological Disorders / Brain Tumors
Investigator: Yazmin Odia, MD
Status: Closed
The purpose of this study is to test whether the new drug, ABT-414, given either alone or with a drug called temozolomide, which is commonly used to treat brain tumors like yours, gives a better outcome than the standard therapy and is safe. The standard therapy can be one of two different regimens, either a drug called lomustine or temozolomide.
Condition: Neurological Disorders
Investigator: Mariam Aly, PhD
Status: Closed
This study seeks to understand which areas of the brain play a role in cognitive processes such as memory, attention, and motivation. We hope to learn how these processes work together and the extent to which Parkinson's disease and the dopaminergic medications prescribed to treat the disease can affect the interplay between them. We are seeking men…
Condition: Psychiatric Disorders / Depression
Investigator: David Hellerstein, MD
Status: Closed
Patients who are either interested in discontinuing their current antidepressant or have discontinued an antidepressant in the past 6 weeks will be provided with an FDA approved medicine, Vortioxetine (brand name Trintellix). Treatment with Vortioxetine will start after the past antidepressant is discontinued. Vortioxetine dosage is adjustable throughout…
Condition: Neurological Disorders / Alzheimer's Disease
Investigator: Lawrence Honig, MD, PhD
Status: Closed
This is a randomized, double-blind, placebo-controlled, parallel-group study that will evaluate the efficacy and safety of gantenerumab versus placebo in participants with prodromal (very early form) to mild AD. Participants will have a chance of receiving either injections of gantenerumab or placebo as per the visit schedule. The primary efficacy…
Condition: Neurological Disorders
Investigator: Lawrence Honig, MD, PhD
Status: Closed
The purpose of this study is to see how safe and well tolerated the study drug BMS-986168 is at different drug amounts and to measure the amount of study drug in your blood and cerebrospinal fluid (CSF) after taking the drug. This study will also measure the effect of the study drug on the amount of extracellular Tau (eTau) in your cerebrospinal fluid, the…
Condition: Psychiatric Disorders / Bipolar Disorder
Investigator: Martin Lan, MD
Status: Closed
We are trying to understand what causes bipolar disorder and how medications treat bipolar depression. Particularly, we are looking at the importance of dopamine signaling in the process. If you participate, you will have two different brain scans (MRI and PET scan). You will also have treatment for your depression with an FDA approved medication,…
Condition: Psychiatric Disorders
Investigator: Ari Shechter, PhD
Status: Closed
We are currently looking for men and women, age 18-65 y, to participate in a sleep study. To participate you must have experienced insomnia (difficulty falling asleep, staying asleep, or experiencing sleep that is unrefreshing) for at least 1 month. This is a 2-phase outpatient and inpatient study. We will test 2 different non-drug based methods to improve…
Condition: Neurological Disorders / Alzheimer's Disease
Investigator: Karen Bell, MD
Status: Closed
The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid. The study will also test 1) whether the anti-amyloid treatment can slow evidence of AD-related brain injury on imaging tests to look at brain structure and function and 2) the effect of…
Condition: Neurological Disorders / Neuromuscular
Investigator: Thomas Brannagan, MD
Status: Closed
Small fiber neuropathy is a painful condition caused by damage to the small nerves in your arms andlegs. This damage causes burning, sharp-stabbing and aching pain, amongst other types of pain. It can be sometimes difficult to know the cause of the damage to the small nerves in your arms and legs. In most cases, treatment for small fiber neuropathy is…
Condition: Neurological Disorders / Neuropathy
Investigator: Thomas Brannagan, MD
Status: Closed
You are being considered to participate in this research study because you have type I or II diabetes with current treatment control and, you are experiencing painful diabetic peripheral neuropathy (DPN) in both lower extremities legs.The specific events that result in painful diabetic peripheral neuropathy are not well understood, but high blood sugar,…
Condition: Neurological Disorders / Brain Tumors
Investigator: Angela Lignelli-Dipple, MD
Status: Closed
The purpose of this research study is to test whether the advanced perfusion MRI done prior to starting Bevacizumab and a few weeks after starting Bevacizumab can determine your response to the treatment better than the standard MRI performed at typical time points. The researchers want to see if this type of advanced MRI is better or the same as what is…
Condition: Psychiatric Disorders / Depression
Investigator: David Hellerstein, MD
Status: Closed
This is a pre-marketing (Phase 2A) multi-site study of an investigational drug, ganaxolone, as a potential treatment for non-psychotic post-partum depression. Eligible subjects who agree by signing informed consent will spend four days on the 5-South Research Unit (5-S) of the New York State Psychiatric Institute. For 6 hours they will have an tube in a…
Condition: Neurological Disorders / Neuromuscular
Investigator: Thomas Brannagan, MD
Status: Closed
This study is designed to test how well an intravenous human immunoglobulin concentrate, IGIV-C (compared with placebo) improves the ability to taper participant's dose of corticosteroids without causing significant increase in your muscle weakness and worsening MG symptoms. A placebo is a medication that looks like the study medication but has no…
Condition: Neurological Disorders / Brain Tumors
Investigator: Andrew Lassman, MD
Status: Closed
This is a two-part research study of an investigational drug called ABBV-321 in subjects with glioblastoma (brain tumor). This study will be conducted in two-parts: 1) Dose Escalation Phase: The purpose of the first part, called a Dose Escalation Phase, is where we will increase the dose of ABBV-321 until we find the highest dose before unmanageable side…
Condition: Psychiatric Disorders / Depression
Investigator: Patrick Brown, PhD
Status: Closed
We are studying the relationship between mitochondrial function and the experience of fatigue. Mitochondria are the powerhouses of the cell. Cells within different organs contain hundreds to thousands of mitochondria, which sustain life and fuel energy-dependent processes that we do every day including muscle contraction and cognitive activity. They act…
Condition: Neurological Disorders
Investigator: Matthew Harms, MD
Status: Closed
This is an observational study designed to collect information about Frontotemporal Lobar Degeneration (FTLD) disorders. FTLD is a term for a related group of neurodegenerative disorders that cause impairments in personality, cognitive ability, language, and motor function. This study aims to build a reliable clinical research network to support treatment…
Condition: Psychiatric Disorders
Investigator: Yuval Neria, PhD
Status: Closed
Columbia University Medical Center is presently recruiting individuals who have experienced trauma to participate in an fMRI research study. For your participation, you will receive up to $270 and an opportunity to advance research in the area of trauma and PTSD. This study involves two visits.
Condition: Neurological Disorders / Neuropathy
Investigator: Thomas Brannagan, MD
Status: Closed
The purpose of this study is to evaluate the efficacy and safety of study drug, fingolimod taken daily compared with a placebo (does not contain active medication) on delaying disability progression in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The study will consist of 3 periods: a Screening Period (lasting for up to 45…
Condition: Neurological Disorders / Brain Tumors
Investigator: Mary Welch, MD
Status: Closed
This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness ofan investigational drug to learn whether the study drug works in treating a specific disease.Investigational means that the drug is being studied. In this research study, we are looking to compare the effects, good and bad, of the standard of care…
Condition: Neurological Disorders / Alzheimer's Disease
Investigator: Davangere Devanand, MD
Status: Closed
This NIH funded research study involves a 12-week double blind treatment trial in which Alzheimer's disease (ages 55-95) who have agitation/aggression with or without psychosis (hallucinations or delusions) will receive either low-dose lithium or placebo. Patients are allowed to receive other specific psychiatric medications if needed during the study…
Condition: Neurological Disorders / Brain Tumors
Investigator: Mary Welch, MD
Status: Closed
The purpose of this study is to investigate a novel treatment regimen for patients with recurrent Glioblastomas (GBM). In this phase 2 trial, the potentially synergistic action of PARP inhibition and anti-angiogenesis on DNA repair and biomarkers of angiogenesis and DNA repair will be evaluated.
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website,
you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the
Columbia University Website Cookie Notice.
I AGREE